A comparative study of damage to liver function after TACE with use of low-dose versus conventional-dose of anticancer drugs in hepatocellular carcinoma

Hepato-Gastroenterology

Volumn 54, Issue 77, 2007, Pages 1499-1502

  Lu, Wei ^a   Li, Yan Hao ^a   Yu, Zhi Jian ^a   He, Xiao Feng ^a   Chen, Yong ^a   Zhao, Jian Bo ^a   Zhu, Zhi Ying ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Antineoplastic agent, combined; Carcinoma, hepatocellular; Chemoembolization, therapeutic; Liver function

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ANTINEOPLASTIC AGENT; CARBOPLATIN; EPIRUBICIN; IODINATED POPPYSEED OIL; MITOMYCIN C;

ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; CHEMOEMBOLIZATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER INJURY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCORING SYSTEM; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, HEPATOCELLULAR; CATHETERIZATION; CHEMOEMBOLIZATION, THERAPEUTIC; EPIRUBICIN; FEMALE; HEPATIC ARTERY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MITOMYCIN;

EID: 34547642691     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Groupe d'Etude et de Traitement du Carcinome hepatocellulaire: A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Eng J Med 1995; 332:1256-1261.
2. Pelletier G, Ducreux M, Gay F, et al: Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J Hepatol 1998; 29:129-34.
3. Kamada K, Nakanishi T, Kitamoto M, et al: Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin lipiodol suspension and doxorubicin hydrochloride emulsion. JVIR 2001; 12:847-854
4. Farinati F, De Maria N, Marafin C, et al: Unresectable hepatocellular carcinoma in cirrhosis: survival, prognostic factor, and unexpected side effects after transcatheter arterial chemoembolization. Dig Dis Sci 1996; 41:2332-2339.
5. Caturelli E, Siena DA, Villani MR, et al: Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of damage to nontumorous liver tissue-long-term prospective study. Radiology 2000; 215:123-128.
6. Lin SC, Shih SC, Kao CR, et al: Transcatheter arterial embolization treatment in patients with hepatocellular carcinoma and risk of pulmonary metastasis World J Gastroenterol 2003; 9:1208-1211.
7. Fan J, Ten GJ, He SC, et al: Arterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 1998; 4:33-37.
8. Chen MS, Li J-Q, Zhang Y-Q, et al: High-dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. World J Gastroenterol 2003; 9:635-640.
9. Xiao EH, Li JQ, Huang JF: Effects of p53 on apoptosis and proliferation of hepatocellular carcinoma cells treated with transcatheter arterial chemoembolization. World J Gastroenterol 2004; 10:190-194.
10. Guo WJ, Yu EX, Liu LM, et al: Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma. World J Gastroenterol 2003; 9:1697-701.
11. Yamada R, Sato M, Nakatsuka H, et al: Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983; 148:397-401.
12. Sacheri S, Lovaria A, Sangiovanni A, et al: Segmental transcatheter arterial chemoembolization treatment in patients with cirrhosis and inoperable hepatocellular carcinomas. J Vasc Interv Radiol 2002; 13:991-994.
13. Mondazzi L, Bottelli R, Brambilla G, et al: Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. Hepatology 1994; 19:1115-1123.
14. Bismuth H, Morino M, Sherlock D, et al: Primary treatment of hepatocellular carcinoma by arterial chemoembolization. Am J Surg 1992; 163:387-394.
15. Bruix J, Llovet JM, Castells A, et al: Transcatheter embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27:1578-1583.
16. Yamasaki S, Hasegawa H, Kinoshita H, et al: A prospective randomized trial on the preventive effect of preoperative transcatheter arterial embolization against recurrence of hepatocellular carcinoma. Jpn J Cancer Res 1996; 87:206-211.
17. Ikeda K, Kumada H, Saitoh S, et al: Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. Cancer 1991; 68:2150-2154.
18. Maeda S, Shibata J, Fujiyama S, et al: Long-term follow-up of hepatic arterial chemoembolization with cisplatin suspended in iodized oil for hepatocellular carcinoma. Hepatogastroenterology 2003; 50:809-813.
19. Berghammer P, Pfeffel F, Winkelbauer F, et al: Arterial hepatic embolization of unresectable hepatocellular carcinoma using a cyanoacylate/lipiodol mixture. Cardiovasc Intervent Radiol 1998; 21: 214-218.
20. Lu W, Li YH, He XF, et al: Transcatheter arterial embolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of two kings of dosages of anticancer-drugs and analysis of Prognostic Factors. Hepatogastroenterology 2003, 50: 2079-2083.
21. Solomon B, Soulen M, Baum RA, et al: Chemoembolization of hepatocellular carcinoma with cisplatin, doxorubicin, mitomycin-C, Ethiodol,and polyvinyl alcohol: prospective evaluation of response and survival evaluation of response and survival in a U.S. population. J Vasc Intervent Radiol 1999; 10:793-798.
22. Florio F, Nardella M, Balzano S, et al: Treatment of hepatocellular carcinoma: a single-center experience. Cardiovasc Intervent Radiol 1997; 20:23-28.